
Sign up to save your podcasts
Or
In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.
Featured Articles:
4.1
4848 ratings
In this week's episode we’ll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.
Featured Articles:
130 Listeners
72 Listeners
320 Listeners
26 Listeners
492 Listeners
273 Listeners
2 Listeners
186 Listeners
362 Listeners
3 Listeners
2 Listeners
29 Listeners
165 Listeners
48 Listeners
1 Listeners